What Are the Different Doxorubicin Side Effects?

[English name] adriamycin [Other names] Doxorubicin, 14-hydroxy daunorubicin, 14-hydroxydaunomycin, Adriamycin, doxorubicin-power, doxorubicin, hydroxy red Bimycin, hydroxyl daunorubicin, doxorubicin, adriamycin, afriamycin, doxorubicin, 14-hydroxydaunomycin, 14-hydroxydaunomycin, etc. Broad antitumor spectrum, suitable for acute leukemia (lymphocytic and granulocyte), malignant lymphoma, breast cancer, bronchial lung cancer (undifferentiated small cell and non-small cell), ovarian cancer, soft tissue sarcoma, osteoblast Tumor, rhabdomyosarcoma, Ewing sarcoma, blastoma, neuroblastoma, bladder cancer, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma, testicular cancer, gastric cancer, liver cancer, etc.

1 Bone marrow hematopoiesis, manifested by platelet and leukopenia.
2 Cardiotoxicity, heart failure may occur in severe cases.
3 Nausea, vomiting,
[Chemical name] (2R, 4S) -4- (3-Amino-2,3,6-trideoxy--L-lyxo-hexopyranosyloxy) -2-hydroxyacetyl-1,2,3,4-tetrahydro-2, 5,12-trihydroxy-7-methoxynaphthacene-6,11-dione
[CA registration number] [23214-92-8]
[Structural formula]
medicine interactions
1. Various bone marrow inhibitors, especially nitrosoureas, high-dose cyclophosphamide or methotrexate, mitomycin, or radiation therapy. If used with the product, the latter amount and total dose should be appropriate Less.
2. If the product is used with streptozotocin, the latter can extend the half-life of the product, so the dose of the former should be reduced.
3. Any drug that may cause liver damage, if used with this product, can increase the liver toxicity of this product; mixed application with heparin, cephalosporin, etc. will easily cause precipitation.
4. This product is cross-resistant to daunorubicin. It is not cross-resistant to methotrexate, fluorouracil, cytarabine, nitrogen mustard, mitomycin, bleomycin, cyclophosphamide, and nitrosourea, and it is not cross-resistant to cyclophosphamide and fluorouracil. , Methotrexate, cisplatin, and nitrosourea drugs have the same degree of synergy.
5. Caution with live virus vaccine during medication.
6. This product can reduce the anticoagulant effect of heparin. ACD and pukamycin used together with this product may cause fatal cardiotoxicity; combined with propranolol, it can strengthen the inhibition of mitochondrial respiratory enzyme activity and increase cardiotoxicity.
[Dosing Instructions]
1. Combined with large doses of cyclophosphamide, the fraction and total amount of this product should be reduced as appropriate.
2. This product is disabled during mediastinal or thoracic radiotherapy. For those who have previously received mediastinal radiation therapy, each dose and total dose of doxorubicin should also be reduced.
3. People who have used sufficient daunorubicin or this product in the past can not use this product again.
4. This product can be used for intraperitoneal administration and bladder perfusion, but not for intrathecal injection.
5. Prevent the product from leaking out of blood vessels. Once it occurs, the local infiltration drug should be drawn as far as possible, and the local immediate injection of 50 to 100 mg of hydrocortisone, or sodium bicarbonate and cold compress.
[Usage and Dosage] Dissolve the sodium chloride injection immediately before use, and the concentration is generally 2mg / ml. Slow intravenous or arterial injection.
1. Usual dose for adults: 50 60mg once, once every 3 4 weeks or 20 30mg per week, for 3 weeks in a row, repeat after 2 3 weeks of discontinuation. Myocardial toxicity, myelosuppression, and gastrointestinal reactions (including oral ulcers) administered in divided doses every week were lighter than those given once every 3 weeks. Children use about half as much as adults. The total dose should not exceed 400 mg / m 2 in terms of body surface area. 30 ~ 40mg can be used in the bladder or chest each time.
2. Combined chemotherapy:
ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), mainly used for Hodgkin's lymphoma;
CAF (cyclophosphamide, the product and fluorouracil), mainly used for breast cancer;
CAOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), mainly used for malignant lymphoma;
FAM (fluorouracil, the product and mitomycin), mainly used for gastric cancer;
AC (the product and cytarabine), mainly used in adult acute myeloid leukemia;
AOP (the product, vincristine and prednisone), mainly used for the induction of remission of lymphoblastic acute leukemia;
ACP (the product, cyclophosphamide and cisplatin), mainly used for ovarian and bronchial lung cancer, head and neck cancer, bladder cancer, etc .;
CY-VA-DIC (cyclophosphamide, vincristine, this product and dacarbazine), mainly used for soft tissue sarcoma and osteosarcoma;
MACC (methotrexate, this product, cyclophosphamide and cyclohexyl nitrosourea), mainly used for undifferentiated small cell lung cancer or lung adenocarcinoma.
[Formulations and specifications] Doxorubicin for injection: 10mg; 50mg.
Adverse reactions
1. Common hair loss (about 90% of patients), myelosuppression (white blood cells drop to the lowest point about 10 to 14 days after administration, and most gradually return to normal levels within 3 weeks, anemia and thrombocytopenia are rare) Mouth ulcers, loss of appetite, nausea, or even vomiting.
2. A small number of patients may have skin redness or pigmentation in the original radiation field after injection of this product. If the injection fluid overflows, it can cause redness, swelling, pain, or even cellulitis and local necrosis.
3. Leukemia and malignant lymphoma patients when using this product, especially those who use the product for the first time, can cause hyperuricemia due to a large number of destruction of tumor cells, resulting in joint pain or renal function damage.
4. This product has cardiotoxicity, which can cause late-onset severe heart failure, which can sometimes occur after half a year of withdrawal. When there is myocardial damage, rapid heart rate, arrhythmia, conduction block, or jet heart failure can occur. These situations can happen suddenly and there is no sign of abnormality in conventional ECG. Myocardial toxicity is closely related to the cumulative dose. For the total amount of 450 to 550 mg / m 2 , the incidence rate is about 1% to 4%. For the total amount of more than 550 mg / m 2 , the incidence rate increases significantly, up to 30%. Cardiotoxicity can be exacerbated by the combined use of other drugs. Newer data suggest that high doses of cyclophosphamide and trastuzumab have similar effects.
Contraindications
1. This product can pass through the placenta, which may cause miscarriage. Therefore, it is strictly prohibited to apply it within the first 3 months of pregnancy. After using this product in pregnant women, toxic reactions to the fetus can sometimes appear up to several years later.
2. Disable the product during mediastinal or thoracic radiotherapy.
3. The following conditions should be disabled: white blood cells below 3500 / l or platelets below 50,000 / l in peripheral blood, obvious infection or fever, cachexia, dehydration, electrolyte or acid-base balance disorders, gastrointestinal obstruction, obvious People with jaundice or impaired liver function, patients with decompensated heart and lung function, patients with chickenpox or shingles.
4. Those who are allergic to this product are prohibited. [1]
1. This product has carcinogenic effects in animals, and also has potential mutagenic and carcinogenic effects in humans. The product has a significant effect on animal reproductive function, but in humans, its inhibitory effect is greatly reduced in rats.
2. Although there is less renal excretion of this product, red urine can appear within 1 to 2 days after administration, and usually disappears after 2 days. Patients with renal insufficiency should be alert to the appearance of hyperuricemia after using this product; patients with gout, if using this product, the amount of allopurinol should be increased accordingly.
3. Elderly patients, children under 2 years old and patients with existing heart disease should be used with extreme caution.
4. A small number of patients can cause jaundice or other liver dysfunction after administration, and the amount of liver dysfunction should be reduced.
5. Check during medication:
Before and after treatment, measure cardiac function, monitor electrocardiogram, echocardiogram, serum enzymes and other myocardial function tests;
Follow-up examination of peripheral blood (at least once a week) and liver function test;
should always check for oral ulcers, diarrhea and jaundice, advise patients to drink plenty of water to reduce the possibility of hyperuricemia, check serum uric acid or renal function if necessary.
6. The cardiotoxicity of doxorubicin mostly occurs 1 to 6 months after discontinuation. Vitamin B6 and coenzyme Q10 should be applied early to reduce its toxicity to the heart.
7. During the medication period, the blood image should be reviewed regularly to avoid bone marrow suppression. [1]
Toxicity test data
Numbering
Toxicity type
testing method
Test object
Dosage used
Toxic effect
1
Acute toxicity
Intravenous injection
Humanity
15 mg / kg / D
1. Cardiotoxicity-cardiomyopathy including infarction 2. Gastrointestinal toxicity-nausea, vomiting 3. Skin and accessory toxicity-changes in hair
2
Acute toxicity
Intravenous injection
Humanity
400 ug / kg
1. Gastrointestinal toxicity-Other changes 2. Hematological toxicity-Leukopenia 3. Skin and accessory toxicity-Hair changes
3
Acute toxicity
Intravenous injection
Humanity
380 mg / kg / 31W
1. Cardiotoxicity-cardiomyopathy including infarction 2. Gastrointestinal toxicity-nausea, vomiting 3. Skin and accessory toxicity-changes in hair
4
Acute toxicity
Not reported
Adult male
243 ug / kg
1. Cardiotoxicity-other changes 2. Vascular toxicity-decreased blood pressure regulation
5
Acute toxicity
Intraperitoneal injection
Rat
16 mg / kg
Detailed effects are not reported other than lethal dose
6
Acute toxicity
Intravenous injection
Rat
10510 ug / kg
1. Nutritional and metabolic system toxicity-weight loss or weight loss rate
7
Acute toxicity
Not reported
Rat
7 mg / kg
Detailed effects are not reported other than lethal dose
8
Acute toxicity
oral
Mouse
570 mg / kg
Detailed effects are not reported other than lethal dose
9
Acute toxicity
Intraperitoneal injection
Mouse
10700 ug / kg
Detailed effects are not reported other than lethal dose
10
Acute toxicity
Intravenous injection
Mouse
10 mg / kg
Detailed effects are not reported other than lethal dose
11
Acute toxicity
trachea
Mouse
2400 ug / kg
1. Nutritional and metabolic system toxicity-weight loss or weight loss rate
12
Acute toxicity
Not reported
Mouse
21900 ug / kg
Detailed effects are not reported other than lethal dose
13
Acute toxicity
Intravenous injection
dog
2400 ug / kg
Detailed effects are not reported other than lethal dose
14
Acute toxicity
Intravenous injection
rabbit
5 mg / kg
Detailed effects are not reported other than lethal dose
15
Acute toxicity
Thoracic injection
rabbit
400 ug / kg
1. Cardiotoxicity-other changes 2. Lung, chest or respiratory toxicity-pulmonary interstitial fibrosis, lung disease (including pneumoconiosis)
3. Lung, chest or respiratory toxicity-thickened pleura
16
Acute toxicity
Parenteral
Hamster
3500 ug / kg
1. Carcinogenicity-anti-tumor and anti-cancer activity
17
Acute toxicity
Intraperitoneal injection
mammal
8500 ug / kg
Detailed effects are not reported other than lethal dose
18
Chronic toxicity
Intraperitoneal injection
Rat
15 mg / kg / 3W-I
1. Cardiotoxicity-other changes 2. Hematological toxicity-changes in serum composition (such as TP, bilirubin, cholesterol)
3. Biochemical toxicity-inhibit or induce phosphatase
19
Chronic toxicity
Intraperitoneal injection
Rat
12 mg / kg / 7D-I
1. Cardiotoxicity-changes in conduction velocity 2. Cardiotoxicity-other changes 3. Biochemical toxicity-inhibition or induction of other enzymes
20
Chronic toxicity
Intraperitoneal injection
Rat
21 mg / kg / 8W-I
1. Liver toxicity-decreased liver function 2. Biochemical toxicity-inhibition or dehydrogenase induction
twenty one
Chronic toxicity
Intraperitoneal injection
Rat
24 mg / kg / 2W-I
1. Cardiotoxicity-changes in electrocardiogram 2. Hematological toxicity-changes in white blood cell count 3. Chronic disease-related toxicity-death
twenty two
Chronic toxicity
Subcutaneous injection
Rat
24 mg / kg / 12W-I
1. Biochemical toxicity-inhibition or induction of dehydrogenase 2. Biochemical toxicity-inhibition or induction of phosphokinase
twenty three
Chronic toxicity
Intraperitoneal injection
Rat
20 mg / kg / 6W-I
1. Cardiotoxicity-changes in heart weight 2. Endocrine toxicity-other changes 3. Hematological toxicity-changes in white blood cell count
twenty four
Chronic toxicity
Intravenous injection
Rat
12 mg / kg / 3W-I
1. Cardiotoxicity-Cardiomyopathy including infarction 2. Cardiotoxicity-Changes in ECG 3. Nutritional and metabolic system toxicity-Weight loss or rate of weight loss
25
Chronic toxicity
Intravenous injection
Rat
20 mg / kg / 10W-I
1. Cardiotoxicity-cardiomyopathy including infarction 2. Chronic disease-related toxicity-death
26
Chronic toxicity
Intravenous injection
Rat
12 mg / kg / 12W-I
1. Cardiotoxicity pulse rate changes 2. Renal, ureter, and bladder toxicity-changes in renal tubules (including acute renal failure, acute tubular necrosis)
3. Hematological toxicity-changes in red blood cell count
27
Chronic toxicity
Intravenous injection
Rat
12 mg / kg / 52D-I
1. Cardiotoxicity-changes in heart weight 2. Kidney, ureter and bladder toxicity-Changes in bladder weight 3. Biochemical toxicity-Inhibition or induction of catalase
28
Chronic toxicity
Intravenous injection
Rat
12 mg / kg / 6W-I
1. Cardiotoxicity-Other changes 2. Biochemical toxicity-Inhibition or induction of phosphatase 3. Biochemical toxicity-Inhibition or induction of dehydrogenase
29
Chronic toxicity
Intravenous injection
Rat
12500 ug / kg / 5D-I
1. Hematological toxicity-Leukopenia 2. Nutrition and metabolic system toxicity-Weight loss or rate of weight loss
30
Chronic toxicity
Intravenous injection
Rat
7 mg / kg / 7W-I
1. Cardiotoxicity-cardiomyopathy including infarction 2. Nutritional and metabolic system toxicity-weight loss or rate of weight loss 3. Chronic disease-related toxicity-death
31
Chronic toxicity
Intravenous injection
Rat
12 mg / kg / 4W-I
1. Cardiotoxicity-Cardiomyopathy including infarction 2. Cardiotoxicity-Changes in ECG 3. Nutritional and metabolic system toxicity-Weight loss or rate of weight loss
32
Chronic toxicity
Intraperitoneal injection
Mouse
10 mg / kg / 9D-I
1. Hepatotoxicity-decreased liver function 2. Biochemical toxicity-Inhibition of transaminase activity, altered the spatial structure of transaminase 3. Nutrition and metabolic system toxicity-changes in calcium concentration
33
Chronic toxicity
Subcutaneous injection
Mouse
27500 ug / kg / 5D-I
1. Chronic disease-related toxicity-death
34
Chronic toxicity
Intravenous injection
Mouse
22600 ug / kg / 2D-I
1. Chronic disease-related toxicity-death
35
Chronic toxicity
Intravenous injection
Mouse
9 mg / kg / 5D-I
1. Hematological toxicity-abnormal staining of red blood cells or affecting nucleated red blood cells 2. Hematological toxicity-reduced white blood cells 3. Hematological toxicity-changes in red blood cell count
36
Chronic toxicity
Intravenous injection
dog
17500 ug / kg / 36W-I
1. Cardiotoxicity-Arrhythmia 2. Lung, chest or respiratory toxicity-Acute pulmonary edema 3. Skin and accessory toxicity-Hair changes
37
Chronic toxicity
Intravenous injection
dog
7250 ug / kg / 5D-I
1. Behavioral toxicity-affects food intake (animals)
2. Gastrointestinal toxicity-excessive exercise, diarrhea 3. Chronic disease-related toxicity-death
38
Chronic toxicity
Intravenous injection
dog
13750 ug / kg / 26W-I
1. Cardiotoxicity-changes in electrocardiogram 2. Vascular toxicity-decreased blood pressure regulation 3. Hematological toxicity-changes in bone marrow
39
Chronic toxicity
Intravenous injection
dog
6250 ug / kg / 18W-I
1. Cardiotoxicity-changes in electrocardiogram
40
Chronic toxicity
Intravenous injection
monkey
23360 ug / kg / 36W-I
1. Cardiotoxicity-Other changes 2. Lung, chest or respiratory toxicity-Acute pulmonary edema 3. Hepatotoxicity-Other changes
41
Chronic toxicity
Intravenous injection
monkey
20800 ug / kg / 5D-I
1. Cardiotoxicity-changes in electrocardiogram 2. Gastrointestinal toxicity-excessive exercise, diarrhea 3. Chronic disease-related toxicity-death
42
Chronic toxicity
Intravenous injection
rabbit
20 mg / kg / 8W-I
1. Cardiotoxicity-changes in cardiac output 2. Vascular toxicity-decreased blood pressure regulation 3. Nutritional and metabolic system toxicity-changes in calcium concentration
43
Chronic toxicity
Intraperitoneal injection
Hamster
27 mg / kg / 3W-I
1. Cardiotoxicity-cardiomyopathy including infarction 2. Skin and accessory toxicity-dermatitis (after systemic exposure)
3. Nutrition and metabolic system toxicity-weight loss or weight loss rate
44
Ocular toxicity
Skin surface
rabbit
15 mg / 24H
45
Mutation toxicity
Salmonella typhimurium
2560 ng / plate
46
Mutation toxicity
Salmonella typhimurium
1 ug / plate
47
Mutation toxicity
Salmonella typhimurium
600 ug / L
48
Mutation toxicity
Salmonella typhimurium
6 ug / plate
49
Mutation toxicity
E.coli
50 mg / L
50
Mutation toxicity
E.coli
10 umol / L
51
Mutation toxicity
E.coli
10 umol / L
52
Mutation toxicity
E.coli
10 umol / L
53
Mutation toxicity
E.coli
1 ug / plate
54
Mutation toxicity
Bacillus subtilis
500 ng / plate
55
Mutation toxicity
Microorganism ed
5 umol / L
56
Mutation toxicity
Microorganism ed
10 umol / L
57
Mutation toxicity
oral
Drosophila melanogaster
1 gm / L
58
Mutation toxicity
Parenteral
Drosophila melanogaster
250 mg / L
59
Mutation toxicity
Saccharomyces cerevisiae
184 umol / L
60
Mutation toxicity
Aspergillus nidulans
100 mg / L
61
Mutation toxicity
Grasshopper cells
250 nmol / L
62
Mutation toxicity
Grasshopper cells
125 nmol / L
63
Mutation toxicity
Non-mammalian testis
1 umol / L
64
Mutation toxicity
Human lymphocyte
20 ug / L
65
Mutation toxicity
Human ovary
10 umol / L
66
Mutation toxicity
Human cells
1250 ug / L
67
Mutation toxicity
Human cells
250 ug / L
68
Mutation toxicity
Human cells
500 nmol / L
69
Mutation toxicity
Human lymphocyte
50 ug / L
70
Mutation toxicity
Human cells
700 nmol / L
71
Mutation toxicity
Human fibroblast
100 umol / L
72
Mutation toxicity
Human fibroblast
500 ug / L
73
Mutation toxicity
Human lymphocyte
100 ug / L
74
Mutation toxicity
Human lymphocyte
1 mg / L
75
Mutation toxicity
Human lymphocyte
10 umol / L
76
Mutation toxicity
Human leukocyte
10 umol / L
77
Mutation toxicity
Hella cells
1 umol / L
78
Mutation toxicity
Human cells
1 umol / L
79
Mutation toxicity
Human cells
10 nmol / L / 2H
80
Mutation toxicity
Human cells
10 nmol / L / 2H
81
Mutation toxicity
Human lymphocyte
500 ug / L
82
Mutation toxicity
Human cells
30 nmol / L
83
Mutation toxicity
Human cells
150 ug / L
84
Mutation toxicity
Human cells
150 ug / L
85
Mutation toxicity
Human cells
50 nmol / L
86
Mutation toxicity
Human cells
400 ug / L
87
Mutation toxicity
Human cells
800 ug / L
88
Mutation toxicity
Human cells
1 umol / L
89
Mutation toxicity
Human leukocyte
20 ug / L
90
Mutation toxicity
Human lymphocyte
10 ug / L
91
Mutation toxicity
Human fibroblast
10 ug / L / 1H
92
Mutation toxicity
Human cells
50 nmol / L
93
Mutation toxicity
Human lymphocyte
5 ng / L / 48H
94
Mutation toxicity
Human cells
1 umol / L
95
Mutation toxicity
Human cells
1 umol / L
96
Mutation toxicity
Intraperitoneal injection
Rat
5 mg / kg
97
Mutation toxicity
Parenteral
Rat
1250 ug / kg / 2D (intermittent)
98
Mutation toxicity
Rat cells
1 ug / L
99
Mutation toxicity
Rat fetus
150 ug / L
100
Mutation toxicity
Rat cells
6800 ug / L
101
Mutation toxicity
Rat liver
6100 nmol / L
102
Mutation toxicity
Rat cells
1150 ug / L
103
Mutation toxicity
Rat cells
1 mg / L
104
Mutation toxicity
Intravenous injection
Rat
5 mg / kg / 8H (intermittent)
105
Mutation toxicity
Rat liver
50 nmol
106
Mutation toxicity
Rat liver
2910 pmol / L
107
Mutation toxicity
Rat mammary gland
100 nmol / L
108
Mutation toxicity
Rat mammary gland
10 umol / L
109
Mutation toxicity
Salmonella typhimurium in rats
200 mg / kg
110
Mutation toxicity
Intraperitoneal injection
Rat
2 mg / kg
111
Mutation toxicity
Intraperitoneal injection
Mouse
2 mg / kg / 24H
112
Mutation toxicity
Mouse lymphocyte
5 ug / L
113
Mutation toxicity
Mouse lymphocyte
100 ug / L
114
Mutation toxicity
Mouse fibroblast
1 ug / L
115
Mutation toxicity
Mouse cells
5 umol / L
116
Mutation toxicity
Mouse cells
2 umol / L
117
Mutation toxicity
Intraperitoneal injection
Mouse
5 mg / kg
118
Mutation toxicity
Mouse leukocytes
260 nmol / L
119
Mutation toxicity
Mouse ascites tumor cells
600 ug / kg
120
Mutation toxicity
Mouse cells
4 umol / L
121
Mutation toxicity
Mouse cells
5 ug / L
122
Mutation toxicity
Mouse leukocytes
10 mg / L
123
Mutation toxicity
Mouse mammary gland
400 ug / L
124
Mutation toxicity
Mouse lymphocyte
20 ug / L
125
Mutation toxicity
Intravenous injection
Mouse
15 mg / kg
126
Mutation toxicity
Mouse cells
100 nmol / L
127
Mutation toxicity
Mouse leukocytes
2900 nmol / L
128
Mutation toxicity
Intraperitoneal injection
Mouse
5 mg / kg
129
Mutation toxicity
Mouse leukocytes
10 mg / L
130
Mutation toxicity
Intraperitoneal injection
Mouse
10 mg / kg
131
Mutation toxicity
Mouse cells
150 ug / L
132
Mutation toxicity
Mouse lymphocyte
6600 ug / L
133
Mutation toxicity
Mouse cells
1800 nmol / L
134
Mutation toxicity
Mouse cells
18 umol / L
135
Mutation toxicity
Mouse lymphocyte
5 ug / L
136
Mutation toxicity
Mouse leukocytes
400 ug / L
137
Mutation toxicity
Intraperitoneal injection
Mouse
500 ug / kg
138
Mutation toxicity
Mouse fibroblast
50 ug / L
139
Mutation toxicity
Intravenous injection
Mouse
500 ug / kg
140
Mutation toxicity
Mouse leukocytes
100 ug / L
141
Mutation toxicity
Parenteral
Mouse
5 mg / kg
142
Mutation toxicity
Intraperitoneal injection
Mouse
250 ug / kg
143
Mutation toxicity
Intravenous injection
Mouse
12 mg / kg
144
Mutation toxicity
Mouse ascites tumor cells
5 mg / kg
145
Mutation toxicity
Mouse lymphocyte
3 mg / kg
146
Mutation toxicity
Mouse lymphocyte
5 gm / L
147
Mutation toxicity
Intravenous injection
Mouse
8 mg / kg
148
Mutation toxicity
Intraperitoneal injection
Mouse
3 mg / kg
149
Mutation toxicity
Mouse lymphocyte
5 ug / L
150
Mutation toxicity
Mouse cells
1 mg / kg
151
Mutation toxicity
Intravenous injection
Mouse
6 mg / kg
152
Mutation toxicity
Hamster lung
100 ug / L
153
Mutation toxicity
Hamster Ovary
1 mg / L
154
Mutation toxicity
Hamster cells
5 mg / L
155
Mutation toxicity
Hamster cells
5 mg / L
156
Mutation toxicity
Hamster Ovary
400 ug / L
157
Mutation toxicity
Hamster lung
300 ug / L / 2H
158
Mutation toxicity
Hamster fibroblast
200 nmol / L
159
Mutation toxicity
Hamster Ovary
1 umol / L
160
Mutation toxicity
Hamster lung
300 ug / L / 2H
161
Mutation toxicity
Hamster lung
10 ug / L
162
Mutation toxicity
Hamster Ovary
160 ug / L
163
Mutation toxicity
Hamster fibroblast
20 nmol / L
164
Mutation toxicity
Chicken cells
5 umol / L
165
Mutation toxicity
Intravenous injection
rabbit
1 mg / kg
166
Carcinogenicity
Intravenous injection
Rat
5 mg / kg
1. Carcinogenicity-Carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
167
Carcinogenicity
Intravenous injection
Rat
8 mg / kg
1. Carcinogenicity-tumor (according to RTECS standards)
2. Skin and accessory toxicity-tumor
168
Carcinogenicity
Intravenous injection
Rat
10 mg / kg
1. Carcinogenicity-Carcinogenic (according to RTECS standards)
2. Lung, chest or respiratory toxicity-tumor 3. Skin and accessory toxicity-tumor
169
Carcinogenicity
Intravenous injection
Rat
5 mg / kg
1. Carcinogenicity-may be carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
170
Carcinogenicity
Intravenous injection
Rat
8 mg / kg
1. Carcinogenicity-Carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
171
Carcinogenicity
Intravenous injection
Rat
10 mg / kg
1. Carcinogenicity-Carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
172
Carcinogenicity
Intravenous injection
Rat
5 mg / kg
1. Carcinogenicity-Carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
173
Carcinogenicity
Intravenous injection
Rat
5 mg / kg
1. Carcinogenicity-may be carcinogenic (according to RTECS standards)
2. Skin and accessory toxicity-tumor
174
Carcinogenicity
Intravenous injection
Rat
2 mg / kg
1. Carcinogenicity-tumor (according to RTECS standards)
2. Skin and accessory toxicity-tumor
175
Reproductive toxicity
Intraperitoneal injection
Rat
8 mg / kg, 6-9 days after conception
1. Reproductive toxicity-abnormal development of the musculoskeletal system
176
Reproductive toxicity
Intraperitoneal injection
Rat
3 mg / kg, 10-12 days after conception
1. Reproductive toxicity-reduced weight gain in newborns
177
Reproductive toxicity
Intraperitoneal injection
Rat
4 mg / kg, 6-9 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
2. Reproductive toxicity-abnormal development of the cardiovascular circulatory system 3. Reproductive toxicity-abnormal development of the urinary system
178
Reproductive toxicity
Intraperitoneal injection
Rat
3 mg / kg, 1 day before male mating
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
2. Reproductive toxicity-changes in testis, epididymis, and vas deferens 3. Reproductive toxicity-decline in male fertility
179
Reproductive toxicity
Intraperitoneal injection
Rat
4200 ug / kg, 7-13 days after conception
1. Reproductive toxicity-abnormal development of the musculoskeletal system 2. Reproductive toxicity-physical changes in newborns
180
Reproductive toxicity
Intraperitoneal injection
Rat
2 mg / kg, 3 days after female conception
1. Reproductive toxicity-increased mortality before embryo implantation 2. Reproductive toxicity-increased mortality after implantation 3. Reproductive toxicity-abnormal development of the musculoskeletal system
181
Reproductive toxicity
Intraperitoneal injection
Rat
8 mg / kg, 9-12 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
2. Reproductive toxicity-abnormal development of the musculoskeletal system
182
Reproductive toxicity
Intravenous injection
Rat
500 ug / kg, male mating 1 day ago
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
183
Reproductive toxicity
Intravenous injection
Rat
10 mg / kg, male mated 1 day ago
1. Reproductive toxicity-changes in testis, epididymis, and vas deferens
184
Reproductive toxicity
Intravenous injection
Rat
3 mg / kg, 1 day before male mating
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
2. Reproductive toxicity-changes in testis, epididymis, and vas deferens
185
Reproductive toxicity
Intravenous injection
Rat
8 mg / kg, male mated 1 day ago
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
186
Reproductive toxicity
Intravenous injection
Rat
8 mg / kg, male mated 1 day ago
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
187
Reproductive toxicity
Parenteral
Rat
61336 ug / kg, male mating 56 days ago
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
188
Reproductive toxicity
Not reported
Rat
4500 ug / kg, 10-12 days after conception
1. Reproductive toxicity-abnormal development of the urinary system 2. Reproductive toxicity-Reduced weight gain in the newborn 3. Reproductive toxicity-affects the behavior of the newborn
189
Reproductive toxicity
Intravenous injection
Mouse
2 mg / kg, male mated 1 day ago
1. Reproductive toxicity-abnormal male spermatogenesis (including genetic material, sperm morphology, sperm motility and count)
190
Reproductive toxicity
Intravenous injection
Mouse
7 mg / kg, 7-13 days after conception
1. Reproductive toxicity-embryo or fetal death 2. Reproductive toxicity-abnormal development of the musculoskeletal system
191
Reproductive toxicity
Intravenous injection
Mouse
700 ug / kg, 7-13 days after conception
1. Reproductive toxicity-physical changes in newborns
192
Reproductive toxicity
Intravenous injection
Mouse
4200 ug / kg, 7-13 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
193
Reproductive toxicity
Intravenous injection
rabbit
7800 ug / kg, 6-18 days after conception
1. Reproductive toxicity-abortion
Material toxicity reference: [2-162]

IN OTHER LANGUAGES

Was this article helpful? Thanks for the feedback Thanks for the feedback

How can we help? How can we help?